Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CASR | P41180 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19195328 | 0.85 | CNR1 (0.88) | CNR1HTTLMNANPC1RAB9A | |
| SCHEMBL8067598 | 0.75 | CNR1 (0.69) | CNR1HTTLMNANPC1RAB9A | |
| SCHEMBL8067593 | 0.75 | CNR1 (0.69) | CNR1HTTLMNANPC1RAB9A | |
| SCHEMBL6373252 | 0.74 | FPR2 (0.73) | CNR1HTTLMNANPC1RAB9A | |
| SCHEMBL3568468 | 0.74 | FPR2 (0.73) | CNR1HTTLMNANPC1RAB9A | |
| SCHEMBL5632770 | 0.74 | FPR2 (0.73) | CNR1HTTLMNANPC1RAB9A | |
| SCHEMBL9125476 | 0.72 | CNR1 (0.61) | CNR1HTTLMNANPC1RAB9A | |
| SCHEMBL9125482 | 0.72 | CNR1 (0.61) | CNR1HTTLMNANPC1RAB9A | |
| SCHEMBL5801215 | 0.71 | CNR1 (0.60) | CNR1LMNANPC1RAB9ACA12 | |
| SCHEMBL8072273 | 0.71 | CNR1 (0.60) | CNR1HTTLMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802503-A1 | UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM | E-Therapeutics plc (GB) | 2021-04-14 | — | — | EP | claimed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3802503-A1 | UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM | E-Therapeutics plc (GB) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | TPH1, KYNU, TPH2 | CNR1 669/4885HTT 290/4885LMNA 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.